In another study, it was shown that miR-630 was significantly decreased in an HER2 positive BC tumor compared to matched peritumor tissue; interestingly, the authors observed that its inhibition in BC cell lines was associated with increased motility, migration, and invasion, and caused a significant increase in the resistance of lapatinib being its target of IGF1R, so they concluded that miR-630 could be a diagnostic and predictive biomarker for resistance to lapatinib and its therapeutic addition may enhance and improve patients’ response to this drug [82]. The gene discussed is IGF1R; the disease is breast cancer.